Abstract:In polypharmacology, ideal drugs are required to bind to multiple specific targets to enhance efficacy or to reduce resistance formation. Although deep learning has achieved breakthrough in drug discovery, most of its applications only focus on a single drug target to generate drug-like active molecules in spite of the reality that drug molecules often interact with more than one target which can have desired (polypharmacology) or undesired (toxicity) effects. In a previous study we proposed a new method named DrugEx that integrates an exploration strategy into RNN-based reinforcement learning to improve the diversity of the generated molecules. Here, we extended our DrugEx algorithm with multi-objective optimization to generate drug molecules towards more than one specific target (two adenosine receptors, A 1 AR and A 2A AR, and the potassium ion channel hERG in this study). In our model, we applied an RNN as the agent and machine learning predictors as the environment , both of which were pre-trained in advance and then interplayed under the reinforcement learning framework. The concept of evolutionary algorithms was merged into our method such that crossover and mutation operations were implemented by the same deep learning model as the agent . During the training loop, the agent generates a batch of SMILES-based molecules. Subsequently scores for all objectives provided by the environment are used for constructing Pareto ranks of the generated molecules with non-dominated sorting and Tanimoto-based crowding distance algorithms. Here, we adopted GPU acceleration to speed up the process of Pareto optimization. The final reward of each molecule is calculated based on the Pareto ranking with the ranking selection algorithm. The agent is trained under the guidance of the reward to make sure it can generate more desired molecules after convergence of the training process. All in all we demonstrate generation of compounds with a diverse predicted selectivity profile toward multiple targets, offering the potential of high efficacy and lower toxicity.

Structure-Aware Dual-Target Drug Design through Collaborative Learning of Pharmacophore Combination and Molecular Simulation

Streamlining Computational Fragment-Based Drug Discovery Through Evolutionary Optimization Informed by Ligand-Based Virtual Prescreening

A Unified Conditional Diffusion Framework for Dual Protein Targets Based Bioactive Molecule Generation

Reprogramming Pretrained Target-Specific Diffusion Models for Dual-Target Drug Design

Integrated Molecular Modeling and Machine Learning for Drug Design

De novo generation of dual-target ligands using adversarial training and reinforcement learning

A Novel Rational PROTACs Design and Validation via AI-Driven Drug Design Approach

Simultaneous Optimization of Drug Combination Dose-Ratio Sequence with Innovative Design and Active Learning

Guided Multi-objective Generative AI to Enhance Structure-based Drug Design

Polypharmacological Drug Design Guided by Integrating Phenotypic and Restricted Fragment Docking Strategies

DrugEx V2: De Novo Design of Drug Molecules by Pareto-based Multi-Objective Reinforcement Learning in Polypharmacology

Design of Multitarget Ligands with an Iterative Fragment-Growing Strategy.

A Novel Strategy for Designing the Magic Shotguns for Distantly Related Target Pairs

Optimizing Drug Design by Merging Generative AI With Active Learning Frameworks

AlphaDrug: Protein Target Specific De Novo Molecular Generation

Towards Structure-Based Protein Drug Design

Designing drugs and chemical probes with the dualsteric approach

Molecular generation strategy and optimization based on A2C reinforcement learning in de novo drug design

Reinforced Genetic Algorithm for Structure-based Drug Design

Target-specific novel molecules with their recipe: Incorporating synthesizability in the design process

Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching.